Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"

Recent papers from Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"

1. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced MelanomaJournal of Clinical Oncology · 2026
2. Abstract B036: Prevalence of non-clear cell renal cell carcinoma based on new WHO classification: Results from a multicenter BUCARE StudyCancer Research · 2026
3. Real-world treatment patterns, healthcare resource utilization, and costs in newly diagnosed patients with rectal cancer in the United StatesColorectal Cancer · 2026
4. Real-time PCR assay for robust detection and global surveillance of the Mycobacterium tuberculosis Haarlem genotypeScientific Reports · 2025
5. Possible Reasons for the Suboptimal Response of the Cladribine Course in Daily Practice: An Independent Analysis of Data from 12 Russian Clinics and the Results of Post-Registration Studies in Other CountriesSclerosis · 2025
6. Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups from the phase 3 CASPIAN studyClinical Lung Cancer · 2025
7. Maintenance avelumab in metastatic urothelial carcinoma: do tumour site and previous surgery matter?BJU International · 2025
8. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 studyCurrent Medical Research and Opinion · 2025
9. First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial癌症：英文版 · 2025
10. Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real‐World, Ambispective RAVE‐Bladder StudyCancer Medicine · 2025
11. Adjuvant Atezolizumab for Early Triple-Negative Breast CancerJAMA · 2025
12. Darya's disease: rare dermatosis with complicated manifestationsRussian Journal of Skin and Venereal Diseases · 2024
13. Distribution of aerogenic carcinogenic risk levels and population mortality from malignant neoplasms on the territory of Omsk cityScientific Bulletin of the Omsk State Medical University · 2024
14. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE TrialJournal of Clinical Oncology · 2024
15. Colon cancer radical surgery postoperative morbidity and mortalitySurgery and Oncology · 2024
16. A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)Frontiers in Oncology · 2024
17. An Integrated Approach to Solving Salmonella Antibiotic Resistance Problem Using Bacteriophages and a Nanosilver-Based PreparationBulletin of KSAU · 2024
18. Effectiveness and safety of empegfilgrastim (Extimia®) in patients with solid tumors receiving cytotoxic therapy: final results of the DEFENDOR studyJournal of Modern Oncology · 2024
19. Outcomes of Placental Abruption Depending on Severity of Pre-Eclampsia: A Multicentre Cohort Observational Retrospective StudyFundamental and Clinical Medicine · 2024
20. Maintenance therapy with avelumab as the first-line treatment in patients with metastatic urothelial carcinoma: A real-world, ambispective RAVE-Bladder study.Journal of Clinical Oncology · 2024